Treatment Selection in Ulcerative Colitis: Optimizing Outcomes through Patient-Centered Decision Making
Podcast 3:
New and Emerging Therapies for UC
Post-Test/Evaluation
Questions marked with a
*
are required
20%
Contact Information
First Name
Last Name
Email Address
Credentials/Degree (MD, DO, RN, etc.)
Date of Participation
Month
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Day
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Year
2018
2019
2020
2021
2022
2023
2024
2025
Which of the following FDA-approved ulcerative colitis (UC) therapies selectively binds to the p19 subunit of interleukin-23?
Upadacitinib
Ozanimod
Ustekinumab
Mirikizumab
A 68-year-old man with type 2 diabetes, hypertension, and moderate to severe congestive heart failure was recently diagnosed with moderate ulcerative colitis (UC). He reports several years of abdominal pain, bleeding, diarrhea and bowel movement urgency. His recent UC flare responded to a course of corticosteroids and he is now being counseled on therapy options. Which of the following would be appropriate for this patient?
Adalimumab
Upadacitinib
Infliximab
Vedolizumab
Start
Powered by
QuestionPro
Loading...
close
drag_indicator
close
Yes
Cancel
Continue
Answer Question
Continue Without Answering
Keep Data
Discard
close